Open-label, multicentre, phase IB dose escalation study of men1611, a pi3k inhibitor combined with tratuzumab +/- fulvestrant, in subjects with pik3ca mutated her2-positive locally recurrent unresectable (advanced) or metastatic (a/m) bresast cáncer progressed to anti-her2 based therapy